Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer

Keyphrases

• Prognostic Factors 100%
• Metastatic Breast Cancer 100%
• Predictive Factors 100%
• Eribulin 100%
• Lymphocyte-to-monocyte Ratio 66%
• Eastern Cooperative Oncology Group 55%
• Group Status 55%
• Treatment Failure 33%
• Predictive Marker 22%
• Treatment Line 22%
• Multivariate Analysis 11%
• Protective Factors 11%
• Time-to-treatment 11%
• Low Risk 11%
• Univariate Analysis 11%
• Adverse Events 11%
• Interactive Effects 11%
• ER + 11%
• Leukopenia 11%
• Combination Therapy 11%
• Response Predictors 11%
• HER2+ 11%
• Clinical Response 11%
• HER2-targeted Therapy 11%
• Triple Negative 11%
• Monotherapy 11%
• Visceral Metastases 11%
• Neutropenia 11%
• Time to Treatment Failure 11%
• Dual Blockade 11%
• Restrospective 11%

Medicine and Dentistry

• Predictive Factor 100%
• Prognostic Factor 100%
• Metastatic Breast Cancer 100%
• Lymphocyte 66%
• Oncology 55%
• Predictive Marker 22%
• Multivariate Analysis 11%
• Cohort Analysis 11%
• Protective Factor 11%
• Biological Marker 11%
• Adverse Event 11%
• Combination Therapy 11%
• Univariate Analysis 11%
• Leukopenia 11%
• Monotherapy 11%
• Neutropenia 11%
• Time to Treatment 11%
• Visceral Metastasis 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Metastatic Breast Cancer 100%
• Eribulin 100%
• Adverse Event 11%
• Combination Therapy 11%
• Biological Marker 11%
• Leukopenia 11%
• Cohort Study 11%
• Monotherapy 11%
• Neutropenia 11%